Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2016 / Article
Special Issue

Oxidative Stress and Inflammation in Hepatic Diseases: Current and Future Therapy

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 7891574 | https://doi.org/10.1155/2016/7891574

Zhanpeng Wang, Zhuonan Li, Yanshuo Ye, Lijuan Xie, Wei Li, "Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets", Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 7891574, 10 pages, 2016. https://doi.org/10.1155/2016/7891574

Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets

Academic Editor: Pablo Muriel
Received04 Jul 2016
Revised30 Sep 2016
Accepted18 Oct 2016
Published10 Nov 2016


Accumulating evidence has indicated that oxidative stress (OS) is associated with the development of hepatocellular carcinoma (HCC). However, the mechanisms remain largely unknown. Normally, OS occurs when the body receives any danger signal—from either an internal or external source—and further induces DNA oxidative damage and abnormal protein expression, placing the body into a state of vulnerability to the development of various diseases such as cancer. There are many factors involved in liver carcinogenesis, including hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic fatty liver disease (NAFLD). The relationship between OS and HCC has recently been attracting increasing attention. Therefore, elucidation of the impact of OS on the development of liver carcinogenesis is very important for the prevention and treatment of liver cancer. This review focuses mainly on the relationship between OS and the development of HCC from the perspective of cellular and molecular mechanisms and the etiology and therapeutic targets of HCC.

1. Introduction

Oxidative stress (OS) is a process whereby the body receives stimulation from harmful endogenous or exogenous factors. Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are common metabolic products of several oxidation-reduction (redox) reactions in the cells, are increased when OS occurs. OS also induces DNA oxidative damage and abnormal protein expression, placing the body into a state of vulnerability. This is closely related to the occurrence and development of various diseases such as diabetes, cancer, and cardiovascular and nervous system diseases [1, 2]. A better understanding of the mechanisms of OS on human illnesses is very important for disease prevention and treatment.

Hepatocellular carcinoma (HCC) is the most common type of hepatic malignant tumor worldwide. Liver cirrhosis is acknowledged as a main risk factor for HCC, and the association rate is high, at 80–90% [3]. Many factors are involved in liver carcinogenesis, including HBV and HCV infection, alcohol abuse, nonalcoholic fatty liver disease (NAFLD), aflatoxin B1, obesity, diabetes, dietary habits, and iron accumulation [4]. Few studies have been conducted on the role of OS in the development of HCC; however, the relationship between OS and the pathogenesis of liver cancer has been attracting increasing attention. This report will provide a review of OS and the development of liver cancer from the perspective of cellular and molecular mechanisms and the etiology and therapeutic targets of HCC.

In general, OS can be triggered by any dangerous or inflammatory signal and affects multiple cells in the liver. The mechanisms of OS on the development of liver cancer are summarized in Figure 1 and are described below.

2.1. Effects of OS on Cytokine Production and Cellular Apoptosis

Liver injury can be either an acute or a chronic inflammatory process. In the environment of local inflammation, many types of liver cells, such as liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), dendritic cells (DCs), and Kupffer cells (KCs), are activated. These cells produce many kinds of immune mediators, cytokines, and chemokines. For example, interleukin- (IL-) 6 is an important proinflammatory cytokine that can inhibit tissue inflammation and cellular apoptosis [5]. Tumor necrosis factor alpha (TNF-α) is a proinflammatory immune mediator that induces tissue damage, produces other cytokines, replenishes inflammatory cells, promotes the occurrence of fibrosis, and further activates the OS reaction [6]. One of the important functions of TNF-α is to activate cellular apoptotic and/or antiapoptotic pathways. The role of TNF-α in the development of HCC remains controversial [7]. OS-associated injury in chronic hepatitis patients is often associated with an increase in fibrosis factor TNF-α and transforming growth factor beta (TGF-β). TGF-β elevation is directly related to the severity of tissue injury and liver fibrosis [8].

Cytokines have been reported to affect liver inflammation, fibrosis, and apoptosis, regulate the process of alcoholic steatohepatitis (ASH)/nonalcoholic steatohepatitis (NASH), and participate in many metabolic changes of ASH/NASH, such as insulin resistance, lipid metabolism, appetite disorders, fever, and increased neutrophils [9].

2.2. OS and Mitochondria, Microsomes, and Telomeres

Mitochondrial dysfunction can impact many important cellular functions, leading to a variety of diseases [10]. New evidence shows that mitochondria play an important role in the process of carcinogenesis. During OS, mitochondrial transcription and replication are increased. The electron transport chain is blocked in the damaged mitochondria, resulting in accumulation of ROS. Further, TNF-α released by liver parenchymal cells and KCs directly damages the mitochondrial respiratory chain, consequently damaging mitochondrial cytochrome oxidase. On the other hand, the production of ROS is increased due to the blockade of any part of the respiratory chain; accumulation of ROS increases oxidative lipid deposition, which induces more lipid peroxidation, inhibiting the respiratory electron transport chain, creating a vicious circle [11]. Another vicious circle is the consumption of antioxidants. Fatty degeneration causes lipid peroxidation, and ROS can consume antioxidant enzymes, glutathione (GSH), and vitamin E; the loss of such protective material can enhance the effect of ROS on mitochondria [11]. Mass accumulation of ROS can change the mitochondrial metabolic process, increase the permeability of the mitochondrial membrane, promote the release of apoptotic factors, and further damage mitochondrial DNA and its additive effects of deletion and mutation [12]. The specific mechanism of signaling pathways becomes clear by illustrating how ROS and cancer-related proteins (p53, oncogenes) regulate mitochondrial functions [13].

Cytochrome P4502E1 (CYP2E1) is a microsomal oxygenase of fatty acid oxidation that can reduce the content of molecular oxygen and generate prooxidants. This process can lead to OS if it is not effectively blocked by an antioxidant. Administration of anti-CYP2E1 serum and a CYP2E1 inhibitor can block the process of OS and protect the cells from damage. In a human experimental liver NASH model, CYP2E1 surrounded the venules and was consistent with the most seriously damaged liver cells. All of these factors have proved that OS in microsomes can induce cell injury [14].

Telomeres play a very important role in cell proliferation, aging, immortalization, and carcinogenesis [15]. Telomere shortening may lead to an end-to-end fusion; consequently, somatic cells stop proliferating and enter into the stage of aging and apoptosis [16]. OS can accelerate the process of telomere shortening and speed up the accumulation of oxidative damage. In comparison with liver tissue from patients who have HCC with or without cirrhosis, HBV or HCV can induce changes in specific genes in the process of DNA repair, cell cycle control, and signal transduction of apoptosis (RASSF1A, GSTP1, CHRNA3, and DOK1 are specific genes that exist in HCC tumors) [17, 18]. According to recent reports, a chronic state of OS may cause migration of reverse transcriptase subunits of telomerase in the cytoplasm, thus reducing the activity of the enzyme. Reduction of the apoptosis signal in cells/tissue is a significant factor in carcinogenesis [1921].

2.3. OS and Genetic Material

OS can cause DNA damage. One study showed that increased liver oxidative damage of DNA, combined with histological fibrosis, is a recognized risk factor for HCC [22]. Chronic viral infections cause liver cell necrosis and inflammation and liver regeneration, all of which are associated with infiltration of immune cells that produce reactive oxygen and nitrogen [23]. DNA damage induced by oxygen free radicals and DNA repair of the adaptation disorder leads to the accumulation of cancer-related gene mutations. There is much evidence that chronic inflammation is one of the causes of human cancer [24, 25]. Oxidative stress and accumulation of DNA damage play an important role in the process of virus-induced cancer [26]. The summary of HCC patients with oxidative DNA damage and inflammation markers was indicated in Table 1.

Ref numberDamage factorsInflammation markers

[13]Mitochondrial dysfunctionp53
[28, 29]HBV, HCV, NASHmiRNA
[30]HBV, HCV, NASHmiRNA-199a, miR-199b, miR-122a, miR-92, miR-222
[48]NASHSulfatase 2
[52]HBVIL-1β, IL-6, CXCL-8, TNF-α
[57]HBV, HCV8-OHdG
[58, 59]HCVFe2+

Circulating free DNA (cfDNA), which mainly comes from the oxide that DNA releases from dead cells, is a kind of DNA with double or single chain strands outside the cells. Circulating free DNA can be released by necrotic cells and apoptotic tumor cells. Low levels of cfDNA can also be detected in healthy people, but a higher level of cfDNA indicates the possibility of the presence of various diseases including cancer [27]. This phenomenon provides the basis for further research on the relationship between HCC and cfDNA.

Recently, microRNA (miRNA), a somewhat small noncoding RNA family (containing 21–23 nucleotides), has been found to play an important role in different phases of the process of HCC development [28]. In fact, miRNA inhibits the translation process by combining specific complementary sequences, or combining with specific complementary sequences on 3′UTR of mRNA to induce the degradation of mRNA [29]. miRNA is considered to be an important mediator in the immune system. Dysfunction of miRNA in inflammatory reactions and oncogenesis is the central event in the development of various cancers. When OS occurs, the expression of a variety of miRNA, as in HCC, is changed. The expression of miRNA-199a, miRNA-199b, and miRNA-122a in most (50%–70%) HCC is strongly downregulated, and the expression of miRNA-92 is indistinctively downregulated. On the contrary, the expression of miRNA-222 is upregulated [30].

2.4. OS and HSCs and KCs

In recent years, studies on the relationship between OS and HSCs have been increasing. HSCs have been proven to play a central part in the process of liver fibrosis [4]. HSCs can induce collagen production after activation in the body by free radicals, which are produced by ROS and superoxide anions, and further induce damage to liver cells [60, 61]. OS can further activate HSCs and stimulate the activity of nuclear factor kappa B (NF-kB). The NF-kB transcription factor is sensitive to redox. Activation of the NF-kB transcription factor can increase the production of nitric oxide (NO) and ROS, which participate in the formation of oxidized low-density lipoprotein (OxLDL) and further activate NF-kB. This creates a vicious circle and results in OS and cell injury [31].

KCs are liver macrophages that serve the functions of phagocytosis, antigen presentation, and immune regulation. KCs can be activated in response to danger of liver infection and produce various cytokines and inflammatory mediators, resulting in aggravation of liver cell injury [8]. Activated KCs produce a large amount of ROS and induce extracellular OS, which can directly cause liver cell necrosis. Other products of KCs, such as H2O2, NO, and various cytokines, may also have toxic effects on liver cells.

3. OS Potentiates Hepatitis Virus Infection and Liver Cell Carcinogenesis

It is known that over 80% of cases of HCC are associated with chronic HBV or HCV infection. Recently, the numbers of patients with obesity, as well as the related conditions of metabolic syndrome and NAFLD, are increasing, and these conditions are becoming an important cause of chronic liver disease in the developed countries, such as European nations and the United States. NAFLD includes simple fatty liver (SFL), nonalcoholic steatohepatitis (NASH), and related cirrhosis. NASH is also considered as one of the causes of liver cancer, and the mechanisms are under investigation. The mechanisms of OS in HBV-, HCV-, and NASH-related HCC are summarized in Figure 2 and are described below.

3.1. NASH-Related HCC and OS

The pathophysiological basis of NASH is a “two-hit” hypothesis. The first hit refers to the fatty degeneration of liver cells, characterized by the accumulation of triglyceride in the liver cells. The second hit includes a variety of cellular stress responses, such as apoptosis, OS, endoplasmic reticulum (ER) stress, and intestinal circumstances [62]. Other studies have demonstrated that the inflammatory response can induce fatty deposition in the liver cells, leading to the “multiple-hit” theory [63]. Fatty toxicity can cause multiple hits to the body, such as OS, ER stress, and immune responses [64]. Cellular stress is also involved in the process of carcinogenesis. The obesity-related diseases such as high blood triglycerides and high blood pressure are definite risk factors of NAFLD. OS is one of the important processes mediated by IL-17, while the IL-17 receptor is widely distributed on the surface of liver cells [32, 33]. The regulation of IL-17-related pathways has been shown to effectively prevent the development of NASH in a mouse model [34]. Patients with increased expression of serum IL-17 have a higher risk of early recurrence of liver cancer after surgery [35]. Thus, OS may be involved in IL-17-mediated NASH-related HCC.

Adiponectin is a protein from fat cells that regulates fat and carbohydrate metabolism [36]. In obese and diabetic patients, the level of adiponectin is usually decreased, and in patients with liver fibrosis, the level of adiponectin usually increases [37]. In HCC, the relationship between the adiponectin level and clinical features of the disease is very complex [38].

Most studies show that adiponectin is a “good” fat factor. Adiponectin has anti-inflammatory, antidiabetic, and anti-fat-accumulation properties; and it participates in energy metabolism, regulation of cell proliferation, and tissue remodeling [39, 40]. Adiponectin also inhibits the growth of cancer cells [41] and induces apoptosis [42], which is directly related to the occurrence and development of cancer [43]. Adiponectin inhibits angiogenesis and thus inhibits the growth and metastasis of liver tumors in mice [44]. Similarly, in a study of human HCC, a lower level of adiponectin has been found to be related to a higher malignant degree of HCC [45]. High adiponectin levels have been found to reduce the risk of prostate cancer, breast cancer, endometrial cancer, colorectal cancer [46], and pancreatic cancer [47]. Adiponectin blocks the protein expression of sulfatase 2 (SULF2), which is oncogenic, and high expression of SULF2 is related to HCC [48]. In addition, the expression levels of adiponectin in primary human liver cancer specimens are lower than in paracancerous tissues [49]. However, other studies have shown that adiponectin increases the risk of liver cancer. Aleksandrova et al. pointed out that non-high-molecular-weight (HMW) adiponectin, not high-molecular-weight adiponectin, was significantly associated with the risk of HCC [50]. Low-molecular forms of adiponectin are more closely associated with inflammation compared to high-molecular forms [51].

3.2. HBV/HCV-Related HCC and OS

HBV- and HCV-related chronic inflammation and fibrosis of the liver are usually induced by OS, which contributes to the pathogenesis of hepatocarcinogenesis. HBV infection results in activation of macrophages to produce a variety of proinflammatory cytokines, such as IL-1β, IL-6, CXCL-8, and TNF-α [52]. Such persistent abnormal production of cytokines and the resulting production of ROS have an influence on hepatocarcinogenesis.

The HBV genome can code a variety of gene products, including DNA polymerase (Pol), the capsid protein (core), envelope proteins L, M, and S, and the multifunctional protein HBx. Many studies have indicated that the HBx protein has carcinogenic potential. Transactivated HBx protein stimulates virus replication and expression and protects the virus-infected cells from damage [53]. The HBx protein is concentrated in the cytoplasm, and the c-terminal region from HBx’s truncation is the producing region of ROS [54]. This phenomenon can be found in 46% of HCC tissue, but not in nonneoplastic tissue [55]. It is an important process in the development of liver cancer that HBV genes integrate into the host genome. Several cancer-related genes, such as TERT, MLL4, and CCNE1, can also be integrated by HBV [65]. HBx is the most common of these genes that are integrated into the human genome.

Studies on analyzing genetic mutations in HBV patients have found that these gene mutations were associated with the occurrence of liver cancer; this emphasizes the importance of HBx on the development of HCC, and OS is involved in this process. A considerable amount of experimental data has proved that the products from the mutant genes in the pre-s area, which accumulate in the ER, have the potential for promoting carcinogenesis through ER stress and the role of ROS [66].

All in all, OS, at least in part, participates in the process of HBV-related liver cancer development through HBx and the pre-s region.

In the state of HCV infection, liver antigen-presenting cells, KCs and DCs, are activated and modulate the immune functions [82]. The most direct impact of HCV on inflammatory signaling pathways is upregulating immunomodulatory molecules such as PD-L1 in KCs [56]. Persistent inflammation causes the liver cells to go into the circulation between the time of apoptosis and regeneration, produces a spontaneous mutation or damage to DNA, and further results in development of HCC [83]. HCV antigens, in particular the core protein, play a key role in the pathogenesis of chronic HCV and hepatocarcinogenesis through the TNFR, PKR, and STAT3 pathways [84]. There are more OS markers (8-OHdG) or reactive oxygen metabolites in the serum of HCV-related HCC patients than in HBV-related HCC patients, suggesting that there is more OS in HCV infection [57]. OS is also associated with senility, which is also one of the driving factors of hepatocarcinogenesis [85].

In addition, during chronic HCV infection, serological markers and iron accumulation in liver cells (especially in the lysosomes) usually are elevated. An excess of bivalent iron is strongly toxic due to induction of Fenton’s reaction, ROS, and hydroxyl free radicals. Iron toxicity is considered to be one of the influencing factors of liver cancer. Some reports have shown that a diet low in iron can reduce the risk of hepatocarcinogenesis in patients with chronic HCV infection [58]. Additional research on iron metabolism and its correlation with liver cancer and OS is underway [59].

OS is associated with the development of HBV-, HCV-, and NASH-related HCC. Therefore, antioxidant treatment to control the causes of HCC is significant. In fact, there are many kinds of antioxidant drugs and foods in our everyday life. However, it is difficult to elucidate their specific effects in vivo and in vitro. Studies on the role of antioxidant effects on liver cancer development are still being conducted. The potential therapeutic targets on HCC of antioxidant treatment are summarized in Table 2.

Ref numberAntioxidant treatmentTargetsPros/cons HCC

[67]CurcuminoidsGlutathione (GSH)↑, P450↓Cons
[68, 69]Ascorbic acid, lipoic acid 
quercetin, mitoquinone, ebselen
[68, 69]ResveratrolGSH↑, ROSCons
[7072]Vitamin EHBV↓, TGF-βCons
[7476]MetforminAMPK↑, Nrf2↑, IL-6↑, 
hemeoxygenase-1 (HO-1)↑
[77, 78]5-Aminoimidazole-4-carboxamide-1-b-ribofuranoside (AICAR)Nrf2↑Cons

It has been reported that curcuminoids could protect DNA from ROS damage, supporting the liver cells during the course of injury and cirrhosis [67]. Studies on chronic HCV infection have also shown that liver function was improved after antiviral treatment. Ascorbic acid, lipoic acid, and quercetin (types of flavonoid antioxidants) and mitoquinone (antioxidant agent target on mitochondria) are also beneficial to patients with chronic HCV infection. The antioxidant properties of resveratrol can reduce liver lipid peroxidation, increase the content of GSH in the liver, and scavenge ROS. The role of resveratrol is mainly in dealing with external liver damage factors such as alcohol intake. In addition, antioxidant drugs composed of ebselen (glutathione peroxidase analogue) have been used in early liver damage caused by alcohol. Studies have shown that vitamin E inhibits HBV replication and TGF-β gene expression in a rat model of NASH [68, 69].

Phlebotomy is considered an effective method against iron overload in patients with hepatitis and NASH [73]. Currently, alternative antioxidant treatment for liver cancer includes, but is not limited to, antioxidant gene therapy, induction of transcription factors AMPK or Nrf2 activator, and activation of oxygen scavengers and drugs that increase the capacity of mitochondrial oxygen intake. As antioxidant, the AMPK agonist metformin and mitochondrial support drug (L-carnitine) is more effective than vitamin E.

Metformin increases the level of AMP in the cells through the activation of AMPK and causes cell cycle arrest, apoptosis, and STAT3-induced IL-6 [74] and antioxidant enzyme of heme oxygenase-1 (HO-1) production [75] through the Nrf2 signaling pathway. A meta-analysis on the drugs of diabetes treatment found that the application of metformin can result in a 50% reduction in the incidence of HCC [76]. The use of 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) as an AMPK activator can induce an increase in the Nrf2 protein and expression of antioxidant enzymes in endothelial cells, whereas AICAR activates Nrf2 in hepatoma cell lines resulting in antioxidant enzyme expression [77]. The combination of metformin and AICAR activates AMPK and Nrf2 for the purpose of controlling liver cancer. OS to normal cells can lead to a cancerous cell phenotype, in turn developing high resistance to further oxidative stress. At present, several clinical trials have found that the OS induced under these conditions can treat liver cancer [78]. The American Association for the Study of Liver Diseases (AASLD) recommends that the dose of vitamin E for the treatment of NASH should be 800 IU/d; in actual application, the dose administered is generally higher than the recommended dose [70]. The selection of the recommended dose was based on a two-year randomized study of NASH, which demonstrated that the dose can improve the level of alanine aminotransferase and histologic activity [71]. However, experimental studies found no beneficial effect on liver fibrosis [72]. Animal studies have shown that an L-carnitine dietary supplement can prevent chemically induced hepatitis and subsequent HCC and NASH-related HCC [79, 80]. Supplementation with L-carnitine was observed to significantly improve plasma glucose levels, lipid profiles, and histological manifestations of NASH patients [81].

5. Conclusion

Accumulating evidence has shown that OS plays an important role in the development of liver cell carcinogenesis through disrupting either normal cell function or genetic materials and interfering with the pathways of signal transduction. Application of antioxidant drugs can control OS damage in vitro. However, so far there has been found no effective antioxidant drug that can be used in vivo. In order to design more effective methods for the prevention and treatment of HCC, investigations into better understanding the mechanisms of liver cancer development, OS damage, and antioxidants are urgently needed (Figure 3).

Competing Interests

The authors declare that they have no competing interests.


The authors acknowledge the Nature Science Foundation of China (NSFC) (81170416; 81273264) and International Cooperation Fund of Jilin Science and Technology Bureau (20160414022GH).


  1. J. Lee, S. Giordano, and J. Zhang, “Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling,” Biochemical Journal, vol. 441, no. 2, pp. 523–540, 2012. View at: Publisher Site | Google Scholar
  2. N. Apostolova, A. Blas-Garcia, and J. V. Esplugues, “Mitochondria sentencing about cellular life and death: a matter of oxidative stress,” Current Pharmaceutical Design, vol. 17, no. 36, pp. 4047–4060, 2011. View at: Publisher Site | Google Scholar
  3. S. Mittal and H. B. El-Serag, “Epidemiology of hepatocellular carcinoma: consider the population,” Journal of Clinical Gastroenterology, vol. 47, pp. S2–S6, 2013. View at: Publisher Site | Google Scholar
  4. E. Mormone, J. George, and N. Nieto, “Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches,” Chemico-Biological Interactions, vol. 193, no. 3, pp. 225–231, 2011. View at: Publisher Site | Google Scholar
  5. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, no. 11, pp. 798–809, 2009. View at: Publisher Site | Google Scholar
  6. J. Djordjevic, A. Djordjevic, M. Adzic, A. Niciforovic, and M. B. Radojcic, “Chronic stress differentially affects antioxidant enzymes and modifies the acute stress response in liver of wistar rats,” Physiological Research, vol. 59, no. 5, pp. 729–736, 2010. View at: Google Scholar
  7. G. C. Leonardi, S. Candido, M. Cervello et al., “The tumor microenvironment in hepatocellular carcinoma (review),” International Journal of Oncology, vol. 40, no. 6, pp. 1733–1747, 2012. View at: Publisher Site | Google Scholar
  8. T. B. Kryston, A. B. Georgiev, P. Pissis, and A. G. Georgakilas, “Role of oxidative stress and DNA damage in human carcinogenesis,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 711, no. 1-2, pp. 193–201, 2011. View at: Publisher Site | Google Scholar
  9. T. Severi, H. van Malenstein, C. Verslype, and J. F. van Pelt, “Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets,” Acta Pharmacologica Sinica, vol. 31, no. 11, pp. 1409–1420, 2010. View at: Publisher Site | Google Scholar
  10. S. Michel, A. Wanet, A. De Pauw, G. Rommelaere, T. Arnould, and P. Renard, “Crosstalk between mitochondrial (dys)function and mitochondrial abundance,” Journal of Cellular Physiology, vol. 227, no. 6, pp. 2297–2310, 2012. View at: Publisher Site | Google Scholar
  11. S. T. Ahmad, W. Arjumand, S. Nafees et al., “Hesperidin alleviates acetaminophen induced toxicity in wistar rats by abrogation of oxidative stress, apoptosis and inflammation,” Toxicology Letters, vol. 208, no. 2, pp. 149–161, 2012. View at: Publisher Site | Google Scholar
  12. A. N. Malik and A. Czajka, “Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction?” Mitochondrion, vol. 13, no. 5, pp. 481–492, 2013. View at: Publisher Site | Google Scholar
  13. S. J. Ralph, S. Rodríguez-Enríquez, J. Neuzil, E. Saavedra, and R. Moreno-Sánchez, “The causes of cancer revisited: ‘Mitochondrial malignancy’ and ROS-induced oncogenic transformation—why mitochondria are targets for cancer therapy,” Molecular Aspects of Medicine, vol. 31, no. 2, pp. 145–170, 2010. View at: Publisher Site | Google Scholar
  14. Z. X. Han, L. Yang, L. Zhang et al., “Influence of electroacupuncture on cytochrome P450 2E1 expression, oxidation, anti-oxidation in non-alcoholic fatty liver tissue,” Chinese Journal of Preventive Medicine, vol. 1, pp. 24–29, 2010. View at: Google Scholar
  15. S. E. Artandi and R. A. DePinho, “Telomeres and telomerase in cancer,” Carcinogenesis, vol. 31, no. 1, pp. 9–18, 2010. View at: Publisher Site | Google Scholar
  16. P. Monaghan, “Telomeres and life histories: the long and the short of it,” Annals of the New York Academy of Sciences, vol. 1206, no. 1, pp. 130–142, 2010. View at: Publisher Site | Google Scholar
  17. M.-P. Lambert, A. Paliwal, T. Vaissière et al., “Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake,” Journal of Hepatology, vol. 54, no. 4, pp. 705–715, 2011. View at: Publisher Site | Google Scholar
  18. C. Ozen, G. Yildiz, A. T. Dagcan et al., “Genetics and epigenetics of liver cancer,” New Biotechnology, vol. 30, no. 4, pp. 381–384, 2013. View at: Publisher Site | Google Scholar
  19. I. Chiodi and C. Mondello, “Telomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria,” Frontiers in Oncology, vol. 2, article 133, 2012. View at: Publisher Site | Google Scholar
  20. I. R. Indran, M. P. Hande, and S. Pervaiz, “hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells,” Cancer Research, vol. 71, no. 1, pp. 266–276, 2011. View at: Publisher Site | Google Scholar
  21. N. K. Sharma, A. Reyes, P. Green et al., “Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria,” Nucleic Acids Research, vol. 40, no. 2, pp. 712–725, 2012. View at: Publisher Site | Google Scholar
  22. T. F. Greten, F. Papendorf, J. S. Bleck et al., “Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients,” British Journal of Cancer, vol. 92, no. 10, pp. 1862–1868, 2005. View at: Publisher Site | Google Scholar
  23. T. Murakami, T. Kim, and H. Nakamura, “Hepatitis, cirrhosis, and hepatoma,” Journal of Magnetic Resonance Imaging, vol. 8, no. 2, pp. 346–358, 1998. View at: Publisher Site | Google Scholar
  24. S. P. Hussain, L. J. Hofseth, and C. C. Harris, “Radical causes of cancer,” Nature Reviews Cancer, vol. 3, no. 4, pp. 276–285, 2003. View at: Publisher Site | Google Scholar
  25. T. Hothorn, B. Lausen, A. Benner, and M. Radespiel-Tröger, “Bagging survival trees,” Statistics in Medicine, vol. 23, no. 1, pp. 77–91, 2004. View at: Publisher Site | Google Scholar
  26. A. G. Georgakilas, W. G. Mosley, S. Georgakila, D. Ziech, and M. I. Panayiotidis, “Viral-induced human carcinogenesis: an oxidative stress perspective,” Molecular BioSystems, vol. 6, no. 7, pp. 1162–1172, 2010. View at: Publisher Site | Google Scholar
  27. C. Alix-Panabières, H. Schwarzenbach, and K. Pantel, “Circulating tumor cells and circulating tumor DNA,” Annual Review of Medicine, vol. 63, no. 1, pp. 199–215, 2012. View at: Publisher Site | Google Scholar
  28. L. Gailhouste, L. Gomez-Santos, and T. Ochiya, “Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer,” Frontiers in Bioscience, vol. 18, no. 1, pp. 199–223, 2013. View at: Publisher Site | Google Scholar
  29. M. S. Ebert and P. A. Sharp, “Roles for microRNAs in conferring robustness to biological processes,” Cell, vol. 149, no. 3, pp. 515–524, 2012. View at: Publisher Site | Google Scholar
  30. C. Romilda, P. Marika, S. Alessandro et al., “Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma,” BMC Cancer, vol. 12, article 177, 2012. View at: Publisher Site | Google Scholar
  31. W. Lin, W.-L. Tsai, R.-X. Shao et al., “Hepatitis C virus regulates transforming growth factor β1 production through the generation of reactive oxygen species in a nuclear factor κB-dependent manner,” Gastroenterology, vol. 138, no. 7, pp. 2509–2518.e1, 2010. View at: Publisher Site | Google Scholar
  32. N. Bhala, R. I. K. Jouness, and E. Bugianesi, “Epidemiology and natural history of patients with NAFLD,” Current Pharmaceutical Design, vol. 19, no. 29, pp. 5169–5176, 2013. View at: Publisher Site | Google Scholar
  33. E. Fabbrini, M. Cella, S. A. McCartney et al., “Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals,” Gastroenterology, vol. 145, no. 2, pp. 366–374.e3, 2013. View at: Publisher Site | Google Scholar
  34. I. T. W. Harley, T. E. Stankiewicz, D. A. Giles et al., “IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice,” Hepatology, vol. 59, no. 5, pp. 1830–1839, 2014. View at: Publisher Site | Google Scholar
  35. J. Wu, J. Du, L. Liu et al., “Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy,” PLoS ONE, vol. 7, no. 12, Article ID e50035, 2012. View at: Publisher Site | Google Scholar
  36. M. Cnop, P. J. Havel, K. M. Utzschneider et al., “Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex,” Diabetologia, vol. 46, no. 4, pp. 459–469, 2003. View at: Publisher Site | Google Scholar
  37. C.-K. Hui, H.-Y. Zhang, N. P. Lee et al., “Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B,” Journal of Hepatology, vol. 47, no. 2, pp. 191–202, 2007. View at: Publisher Site | Google Scholar
  38. A. B. Siegel, A. Goyal, M. Salomao et al., “Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients,” Oncology, vol. 88, no. 1, pp. 57–68, 2015. View at: Publisher Site | Google Scholar
  39. M. J. Gunter and M. F. Leitzmann, “Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes,” Journal of Nutritional Biochemistry, vol. 17, no. 3, pp. 145–156, 2006. View at: Publisher Site | Google Scholar
  40. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B. D. Murphy, and M.-F. Palin, “Adiponectin action from head to toe,” Endocrine, vol. 37, no. 1, pp. 11–32, 2010. View at: Publisher Site | Google Scholar
  41. A. Y. Kim, Y. S. Lee, K. H. Kim et al., “Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation,” Molecular Endocrinology, vol. 24, no. 7, pp. 1441–1452, 2010. View at: Publisher Site | Google Scholar
  42. J.-S. Byeon, J.-Y. Jeong, M. J. Kim et al., “Adiponectin and adiponectin receptor in relation to colorectal cancer progression,” International Journal of Cancer, vol. 127, no. 12, pp. 2758–2767, 2010. View at: Publisher Site | Google Scholar
  43. A. La Cava, “Adiponectin: a relevant player in obesity-related colorectal cancer?” Gut, vol. 62, no. 4, pp. 483–484, 2013. View at: Publisher Site | Google Scholar
  44. K. Man, K. T. P. Ng, A. Xu et al., “Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling,” Clinical Cancer Research, vol. 16, no. 3, pp. 967–977, 2010. View at: Publisher Site | Google Scholar
  45. S. Sumie, T. Kawaguchi, R. Kuromatsu et al., “Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection,” PLoS ONE, vol. 6, no. 11, Article ID e26840, 2011. View at: Publisher Site | Google Scholar
  46. V. Izadi, E. Farabad, and L. Azadbakht, “Serum adiponectin level and different kinds of cancer: a review of recent evidence,” ISRN Oncology, vol. 2012, Article ID 982769, 9 pages, 2012. View at: Publisher Site | Google Scholar
  47. Y. Bao, E. L. Giovannucci, P. Kraft et al., “A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts,” Journal of the National Cancer Institute, vol. 105, no. 2, pp. 95–103, 2013. View at: Publisher Site | Google Scholar
  48. M. M. H. Al-Gayyar, A. Abbas, and A. M. Hamdan, “Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma,” Biological Chemistry, vol. 397, no. 3, pp. 257–267, 2016. View at: Publisher Site | Google Scholar
  49. S.-Q. Xing, C.-G. Zhang, J.-F. Yuan, H.-M. Yang, S.-D. Zhao, and H. Zhang, “Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins,” Biochemical Pharmacology, vol. 93, no. 2, pp. 221–231, 2015. View at: Publisher Site | Google Scholar
  50. K. Aleksandrova, H. Boeing, U. Nöthlings et al., “Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer,” Hepatology, vol. 60, no. 3, pp. 858–871, 2014. View at: Publisher Site | Google Scholar
  51. F. Schober, M. Neumeier, J. Weigert et al., “Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release,” Biochemical and Biophysical Research Communications, vol. 361, no. 4, pp. 968–973, 2007. View at: Publisher Site | Google Scholar
  52. M. Hösel, M. Quasdorff, K. Wiegmann et al., “Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection,” Hepatology, vol. 50, no. 6, pp. 1773–1782, 2009. View at: Publisher Site | Google Scholar
  53. C. Xu, W. Zhou, Y. Wang, and L. Qiao, “Hepatitis B virus-induced hepatocellular carcinoma,” Cancer Letters, vol. 345, no. 2, pp. 216–222, 2014. View at: Publisher Site | Google Scholar
  54. S.-Y. Jung and Y.-J. Kim, “C-terminal region of HBx is crucial for mitochondrial DNA damage,” Cancer Letters, vol. 331, no. 1, pp. 76–83, 2013. View at: Publisher Site | Google Scholar
  55. K. M. F. Sze, G. K. Y. Chu, J. M. F. Lee, and I. O. L. Ng, “C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma,” Hepatology, vol. 57, no. 1, pp. 131–139, 2013. View at: Publisher Site | Google Scholar
  56. Z. Tu, R. H. Pierce, J. Kurtis, Y. Kuroki, I. N. Crispe, and M. S. Orloff, “Hepatitis C virus core protein subverts the antiviral activities of human kupffer cells,” Gastroenterology, vol. 138, no. 1, pp. 305–314, 2010. View at: Publisher Site | Google Scholar
  57. M. Nishimura, A. Takaki, N. Tamaki et al., “Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma,” Hepatology Research, vol. 43, no. 10, pp. 1078–1092, 2013. View at: Publisher Site | Google Scholar
  58. T. Yamasaki, S. Terai, and I. Sakaida, “Deferoxamine for advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 365, no. 6, pp. 576–578, 2011. View at: Publisher Site | Google Scholar
  59. S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012. View at: Publisher Site | Google Scholar
  60. N. Kawelke, M. Vasel, C. Sens, A. von Au, S. Dooley, and I. A. Nakchbandi, “Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β,” PLoS ONE, vol. 6, no. 11, article e28181, 2011. View at: Publisher Site | Google Scholar
  61. J. Bosch, J. G. Abraldes, M. Fernández, and J. C. García-Pagán, “Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension,” Journal of Hepatology, vol. 53, no. 3, pp. 558–567, 2010. View at: Publisher Site | Google Scholar
  62. A. Carazo, J. León, J. Casado et al., “Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1,” Obesity Surgery, vol. 21, no. 4, pp. 492–500, 2011. View at: Publisher Site | Google Scholar
  63. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at: Publisher Site | Google Scholar
  64. A. Takaki, D. Kawai, and K. Yamamoto, “Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH),” International Journal of Molecular Sciences, vol. 15, no. 5, pp. 7352–7379, 2014. View at: Publisher Site | Google Scholar
  65. W.-K. Sung, H. Zheng, S. Li et al., “Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma,” Nature Genetics, vol. 44, no. 7, pp. 765–769, 2012. View at: Publisher Site | Google Scholar
  66. T. Pollicino, I. Cacciola, F. Saffioti, and G. Raimondo, “Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications,” Journal of Hepatology, vol. 61, no. 2, pp. 408–417, 2014. View at: Publisher Site | Google Scholar
  67. T. Osawa, “Nephroprotective and hepatoprotective effects of curcuminoids,” Advances in Experimental Medicine and Biology, vol. 595, pp. 407–423, 2007. View at: Publisher Site | Google Scholar
  68. M. Esrefoglu, “Oxidative stress and benefits of antioxidant agents in acute and chronic hepatitis,” Hepatitis Monthly, vol. 12, no. 3, pp. 160–167, 2012. View at: Publisher Site | Google Scholar
  69. H.-L. Ha, H.-J. Shin, M. A. Feitelson, and D.-Y. Yu, “Oxidative stress and antioxidants in hepatic pathogenesis,” World Journal of Gastroenterology, vol. 16, no. 48, pp. 6035–6043, 2010. View at: Publisher Site | Google Scholar
  70. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at: Publisher Site | Google Scholar
  71. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at: Publisher Site | Google Scholar
  72. J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner et al., “Vitamin e and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 2, pp. 134–143, 2013. View at: Publisher Site | Google Scholar
  73. K. Hino, Y. Hara, and S. Nishina, “Mitochondrial reactive oxygen species as a mystery voice in hepatitis C,” Hepatology Research, vol. 44, no. 2, pp. 123–132, 2014. View at: Publisher Site | Google Scholar
  74. X. Cai, X. Hu, B. Cai et al., “Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo,” Oncology Reports, vol. 30, no. 5, pp. 2449–2457, 2013. View at: Publisher Site | Google Scholar
  75. X. M. Liu, K. J. Peyton, A. R. Shebib, H. Wang, R. J. Korthuis, and W. Durante, “Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 300, no. 1, pp. H84–H93, 2011. View at: Publisher Site | Google Scholar
  76. S. Singh, P. P. Singh, A. G. Singh, M. H. Murad, and W. Sanchez, “Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis,” American Journal of Gastroenterology, vol. 108, no. 6, pp. 881–891, 2013. View at: Publisher Site | Google Scholar
  77. B. Sid, C. Glorieux, M. Valenzuela et al., “AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells,” Biochemical Pharmacology, vol. 91, no. 2, pp. 168–180, 2014. View at: Publisher Site | Google Scholar
  78. D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009. View at: Publisher Site | Google Scholar
  79. B. Chang, M. Nishikawa, S. Nishiguchi, and M. Inoue, “L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria,” International Journal of Cancer, vol. 113, no. 5, pp. 719–729, 2005. View at: Publisher Site | Google Scholar
  80. H. Ishikawa, A. Takaki, R. Tsuzaki et al., “L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway,” PLoS ONE, vol. 9, no. 7, Article ID e100627, 2014. View at: Publisher Site | Google Scholar
  81. M. Malaguarnera, M. P. Gargante, C. Russo et al., “L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitisa randomized and controlled clinical trial,” American Journal of Gastroenterology, vol. 105, no. 6, pp. 1338–1345, 2010. View at: Publisher Site | Google Scholar
  82. A. Boltjes, D. Movita, A. Boonstra, and A. M. Woltman, “The role of Kupffer cells in hepatitis B and hepatitis C virus infections,” Journal of Hepatology, vol. 61, no. 3, pp. 660–671, 2014. View at: Publisher Site | Google Scholar
  83. A. Arzumanyan, H. M. G. P. V. Reis, and M. A. Feitelson, “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma,” Nature Reviews Cancer, vol. 13, no. 2, pp. 123–135, 2013. View at: Publisher Site | Google Scholar
  84. S. Shen, M. Niso-Santano, S. Adjemian et al., “Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity,” Molecular Cell, vol. 48, no. 5, pp. 667–680, 2012. View at: Publisher Site | Google Scholar
  85. G. Paradies, G. Petrosillo, V. Paradies, and F. M. Ruggiero, “Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging,” Free Radical Biology and Medicine, vol. 48, no. 10, pp. 1286–1295, 2010. View at: Publisher Site | Google Scholar

Copyright © 2016 Zhanpeng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.